Bristol-Myers Braces For Blow In Class Action Suit

Law360, New York (January 23, 2006, 12:00 AM EST) -- For Bristol-Myers Squibb Co., when it rains it pours. In its latest effort to snuff out an unrelenting barrage of complaints from shareholders, the company has set aside $185 million in anticipation of settling a securities class action lawsuit over an experimental heart drug the company touted as a future blockbuster that later proved to be potentially fatal.

The lawsuit, filed in a federal court in New Jersey in 2000, alleges the pharmaceutical giant continued to hype its experimental heart drug Vanlev despite poor clinical trial...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.